Jaguar Health, Inc. JAGX
Jaguar Health, Inc. ("Jaguar"), in conjunction with Jaguar family company Napo Pharmaceuticals, Inc. ("Napo"), develops novel proprietary prescription drugs sustainably derived from plants for people with complicated gastrointestinal ("GI") disease states. Jaguar family companies Napo and Napo Therapeutics, S.p.A., an Italian corporation Jaguar was established in Milan, Italy in 2021, are focused on expanding global crofelemer access and are developing new therapies for orphan and rare GI conditions. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp., is focused on developing novel prescription medicines derived from plants for mental health indications.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $11.5M | $11.7M | $9.8M | $12.0M | $4.3M | $9.4M | $5.8M | $4.4M | $4.4M | $141.5K |
| Cost of revenue | $3.8M | $2.0M | $2.0M | $2.0M | $2.3M | $3.3M | $3.8M | $2.8M | $880.4K | $52.0K |
| Gross profit | $7.7M | $9.7M | $7.7M | $9.9M | $2.0M | $6.1M | $2.0M | $1.7M | $3.5M | $89.6K |
| R&D | $25.0M | $16.5M | $18.6M | $17.6M | $15.1M | $6.4M | $5.8M | $5.2M | $4.3M | $7.2M |
| SG&A | $18.6M | $16.3M | $16.6M | $17.9M | $17.1M | $14.4M | $13.5M | $12.3M | $11.2M | $6.0M |
| Total operating expenses | $57.4M | $42.5M | $44.1M | $46.4M | $45.0M | $36.0M | $34.7M | $35.2M | $38.6M | $13.7M |
| Operating income | -$45.9M | -$30.8M | -$34.3M | -$34.4M | -$40.7M | -$26.6M | -$28.9M | -$30.8M | -$34.2M | -$13.6M |
| Interest expense | $67.0K | $231.0K | $6.4M | $12.7M | $8.4M | $2.8M | $5.7M | $2.6M | $1.2M | $985.5K |
| Pre-tax income | -$54.0M | -$39.3M | -$41.9M | -$48.4M | -$52.6M | -$33.8M | -$38.5M | -$32.1M | -$35.1M | -$14.7M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $10.0K | — | $13.2M | — |
| Net income | -$54.0K | -$39.2K | -$41.9K | -$48.4K | -$52.6K | -$33.8M | -$38.5M | -$32.1M | -$22.0M | -$14.7M |
| EPS, basic | -22.97 | -130.69 | -2,678.17 | -36.18 | -88.22 | -3.00 | — | — | — | — |
| EPS, diluted | -22.97 | -130.69 | -2,678.17 | -36.18 | -88.22 | -3.00 | -9.01 | -153.27 | -7.59 | -1.35 |
| Shares, diluted (wtd. avg.) | 2.3M | 294,534 | 15,421 | 1.3M | 596,154 | 12.9M | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $968.0K | $8.0M | $6.5M | $5.5M | $17.1M | $8.1M | $3.9M | $2.6M | $759.9K | $1.5M |
| Receivables | $1.5M | $1.5M | $2.0M | $1.9M | $1.7M | $2.1M | $1.7M | $995.7K | $467.7K | $5.0K |
| Inventory | $8.6M | $10.3M | $9.2M | $7.0M | $4.9M | $2.8M | $2.1M | $3.3M | $2.1M | $412.8K |
| Total current assets | $20.3M | $32.2M | $28.0M | $22.3M | $28.4M | $17.8M | $9.5M | $8.1M | $3.8M | $2.6M |
| Property, plant and equipment | $463.0K | $464.0K | $496.0K | $557.0K | $650.0K | $677.0K | $710.0K | $760.6K | $1.2M | $885.9K |
| Goodwill | — | — | — | — | — | — | — | $5.2M | $5.2M | — |
| Other intangibles | $16.0M | $18.5M | $20.1M | $22.4M | $22.7M | $24.3M | $26.0M | $31.7M | $33.4M | — |
| Total assets | $38.3M | $53.4M | $50.8M | $47.5M | $53.3M | $42.8M | $36.4M | $41.0M | $43.6M | $3.6M |
| Accounts payable | $8.7M | $5.3M | $5.0M | $5.8M | $4.9M | $4.8M | $5.4M | $5.4M | $7.4M | $517.0K |
| Short-term debt | — | — | — | — | — | — | — | — | $1.6M | $1.9M |
| Total current liabilities | $40.7M | $19.7M | $14.0M | $30.3M | $15.5M | $13.2M | $15.4M | $26.7M | $15.4M | $4.2M |
| Long-term debt | — | — | — | — | — | — | — | — | — | $1.8M |
| Total liabilities | $57.0M | $44.4M | $45.9M | $48.8M | $41.4M | $25.6M | $15.8M | $26.7M | $26.4M | $6.0M |
| Retained earnings | -$399.9M | -$346.5M | -$308.2M | -$266.9M | -$219.5M | -$166.9M | -$133.1M | -$94.6M | -$62.4M | -$40.4M |
| Total equity | -$18.7M | $6.5M | $4.9M | -$1.4M | $11.9M | $17.2M | $10.7M | $5.4M | $17.3M | -$2.5M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$23.7M | -$29.4M | -$33.2M | -$33.1M | -$35.0M | -$15.3M | -$20.5M | -$22.7M | -$9.8M | -$14.4M |
| Depreciation and amortisation | $1.9M | $1.9M | $2.0M | $2.0M | $1.7M | $1.7M | $1.7M | $1.3M | $584.3K | $47.5K |
| Stock-based compensation | $831.0K | $1.6M | $2.1M | $3.3M | $4.0M | $2.8M | $3.0M | $2.0M | $814.6K | $717.9K |
| Capital expenditure | — | $16.0K | — | $77.0K | $6.0K | $7.0K | — | $6.5K | — | $104.2K |
| Investing cash flow | -$41.0K | -$231.0K | — | -$1.7M | -$6.0K | -$7.0K | — | -$6.5K | -$1.6M | $2.4M |
| Financing cash flow | $23.7M | $31.2M | $34.2M | $23.2M | $43.9M | $19.5M | $21.8M | $24.5M | $10.7M | $5.3M |
| Buybacks | — | — | — | — | — | — | — | $30 | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-192753.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $141.5K | $4.4M | $4.4M | $5.8M | $9.4M | $4.3M | $12.0M | $9.8M | $11.7M | $11.5M |
| Gross profit | $89.6K | $3.5M | $1.7M | $2.0M | $6.1M | $2.0M | $9.9M | $7.7M | $9.7M | $7.7M |
| Net income | -$14.7M | -$22.0M | -$32.1M | -$38.5M | -$33.8M | -$52.6K | -$48.4K | -$41.9K | -$39.2K | -$54.0K |
Recent filings and events
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Other event Item 8.01
- Material agreement signed Item 1.01
- Other event Item 8.01
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Regulation FD disclosure Item 7.01
- Material agreement signed Item 1.01
- New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Material agreement signed Item 1.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |